Grants and Contracts
Congratulations to the following individuals for obtaining extramural funding from federal, state, and/or independent sources between May 1 – July 31, 2023!
NOTE: If any information has been inadvertently omitted, please contact the editor (dflock@lsuhsc.edu) and a correction will be printed in the next issue of The Pulse.
National Institutes of Health (R21)
Jason Gardner, PhD (Physiology)
“Role of Novel RNA Binding Protein LARP6 in Alcoholic Cardiomyopathy”
Rajani Maiya, PhD (Physiology)
“Molecular Signatures of Social Stress-induced Escalation of Drinking”
National Institutes of Health (F30)
Taylor Fitzpatrick-Schmidt (Physiology)
“Interactions of Alcohol and Pain in the Context of HIV”
National Institutes of Health (K08)
Rajesh Mohandas, MD (Medicine/Nephrology)
“Vascular Smooth Muscle Lysyl Oxidase Mediated Increase in Vessel Stiffness and its
Effect on Rho-Kinase Mechanosensors”
U.S. Department of Defense
Shyamal Desai, PhD (Biochemistry and Molecular Biology)
“Clinical Development of ISGylation Diagnostic Biomarker for ALS”
LA Board of Regents Educational Quality Support Fund
Ben Kelly, PhD (Microbiology, Immunology and Parasitology)
"Regulation of Cytochrome C Oxidase Subunit Expression in Leishmania"
LSU LIFT Grant
Xiaolin Tian, PhD (Neuroscience Center of Excellence)
“Gene Therapy as a Potential Treatment for Alzheimer's Disease”
University Collaboration
Lauri Byerley, PhD (Physiology)
Viterbo University
“The Research Practice Group Mid/Late Career Faculty Grant Award”
Canadian Institute of Health
Jeff Xiang Ji (Neuroscience Center of Excellence)
“Understanding Elovanoids Mechanisms of Neuroprotection in Experimental Ischemic Stroke”
Pharmaceutical, Professional Society and Private Grants
Jameel Ahmed, MD (Medicine/Cardiology)
Janssen Research and Development, LLC
“A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled
Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor,
Versus Apixaban in Participants with Atrial Fibrillation”
Juzar Ali, MD (Medicine/Pulmonary-Critical Care)
Paratek Pharmaceuticals, Inc.
“A Phase 2, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Multi-Center
Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Omadacycline in Adult
Subjects with Nontuberculous Mycobacterial (NTM) Pulmonary Disease”
Amelia Jernigan, MD (OB-GYN)
Acrivon Therapeutics, Inc.
“A Phase 1B/2 Basket Study of ACR-368 as Monotherapy and in Combination with Gemcitabine
in Adult Subjects with Platinum-Resistant Ovarian Carcinoma, Endometrial Denocarcinoma,
and Urothelial Carcinoma based on Acrivon Oncosignature®"
Amita Krishnan, MD (Medicine/Pulmonary-Critical Care)
United Therapeutics Corporation
“Pulmonary Hypertension Screening in Patients with Interstitial Lung Disease for Early
Detection”
Rebecca Lillis, MD (Medicine/Infectious Diseases)
Becton Dickinson Corp.
“Clinical Validation of the BD Elience™ POC CT/GC Assay”
Michelle Loch, MD (Medicine/Hematology and Oncology)
Pfizer, Inc.
“A Phase 3, Randomized, Open-label, Multicenter Trial of ARV-471 (PF-07850327) vs.
Fulvestrant in Participants with Estrogen Receptor-Positive, HER2-Negative Advanced
Breast Cancer whose Disease Progressed After Prior Endocrine-Based Treatment”
Mary Maluccio, MD (Surgery)
Parexel International Corp.
“A Randomized, Parallel Group Study to Evaluate the Safety, Pharmacokinetics, and
Dose Response of Paltusotine Treatment in Subjects with Carcinoid Syndrome”
Stephen Morse, DO (Medicine/Nephrology)
Vertex Pharmaceuticals
“Phase 2/3 Adaptive, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy
and Safety pf VX-147 in Subjects Aged 18 Years and Older with APOL1-mediated Proteinuric
Kidney Disease”
Lisa Peacock, MD (OB-GYN)
Medtronic
“Medtronic Fellowship”
Frank Smart, MD (Medicine/Cardiology)
Cordio Medical Ltd.
“An International, Multicenter, Observational, Single-Arm, Blinded Study to Assess
the Performance of the Corio HearOTM System”
Frank Smart, MD (Medicine/Cardiology)
Alleviant Medical, Inc.
“Safety and Efficacy of the ALLeviAnt SYstem for No-Implant Interatrial Shunt Creation
in Patients with Chronic Heart Failure”